HL 301

Drug Profile

HL 301

Alternative Names: HL301

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Hanlim Pharmaceutical
  • Developer Hanlim Pharmaceutical; HL Genomics
  • Class Antibronchitics; Herbal medicines; Traditional-Chinese-medicine
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bronchitis

Most Recent Events

  • 01 Mar 2014 Phase-II clinical trials in Bronchitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top